Sandoz India Appoints Vishal Rathi as Group Head of Product Development

Sandoz India has appointed Vishal Rathi as Group Head, Product Development, a move that signals renewed focus on the company's generics and biosimilar pipeline at a time when Indian manufacturers face intensifying regulatory scrutiny across both domestic and export markets.

Rathi's appointment places dedicated leadership over a function that sits at the intersection of formulation science, process validation, and regulatory submission readiness. For QA directors and regulatory affairs leads within the Sandoz India network, the structural change suggests pipeline decisions and dossier timelines may see tighter coordination under a single accountable head.

Sandoz operates within the Novartis-spun generics framework and has maintained a dual focus on small-molecule generics and biosimilar development in India. Product development leadership at this level typically carries responsibility for aligning development activities with ICH Q10 pharmaceutical quality system requirements and ensuring that technology transfer protocols meet the standards expected under 21 CFR Part 211 for any US-facing submissions.

The appointment comes as Indian generics manufacturers continue to navigate a demanding inspection environment, with USFDA and European regulatory bodies maintaining active oversight of Indian facilities. A dedicated group head role consolidates accountability for development-stage decisions that downstream affect GMP compliance, stability data packages, and submission timelines.

No further details on Rathi's prior roles or the scope of direct reports were available in the source disclosure.

The measurable indicator to watch is the pace and regulatory quality of new product filings attributed to the Sandoz India development function over the next two annual cycles.

Source: Media4Growth via Indian Pharma Post, 24 June 2026.